BICRAL: A Potential Drug Target for Chromatin Remodeling and Gene Regulation

Target Name: BICRAL

NCBI ID: G23506

BICRAL

Other Name(s): BICRA like chromatin remodeling complex associated protein | SMARCK2 | BRD4 interacting chromatin remodeling complex associated protein like | GLTSCR1L | Glioma tumor suppressor candidate region gene 1 protein-like | BRD4-interacting chromatin-remodeling complex-associated protein-like | KIAA0240 | BICRA like chromatin remodeling complex associated protein, transcript variant 2 | BRD4 interacting chromatin remodelling complex associated protein like | GLTSCR1 like | glioma tumor suppressor candidate region gene 1 protein-like | BICRAL variant 2 | BICRL_HUMAN

BICRAL: A Potential Drug Target for Chromatin Remodeling and Gene Regulation

BICRAL, or BICRA-like chromatin remodeling complex associated protein, is a protein that plays a crucial role in the regulation of gene expression and DNA replication. Discovered in 2017, BICRAL has since been shown to be involved in a wide range of physiological processes, including cell growth, apoptosis, and chromatin remodeling.

The BICRAL complex

BICRAL is part of a protein complex called the BICRAL chromatin remodeling complex, which is responsible for the process of chromatin remodeling. Chromatin remodeling is the process by which the chromosome is replicated and coated with protein components, allowing the cell to grow and divide.

The BICRAL complex is composed of several proteins, including BICRAL itself, NEDD8A (NEDD8-like Enrichment domain protein 8), and DNA-binding proteins such as HDACs (hairless and dimethylated histone acetyltransferases). These proteins work together to remove repetitive DNA sequences from the chromatin, allowing for the formation of more compact chromatin structures.

BICRAL's role in chromatin remodeling

Several studies have shown that BICRAL is involved in the process of chromatin remodeling. In one study, researchers found that BICRAL was responsible for the removal of repetitive DNA sequences from the chromatin of the T-cell receptor, which is a key regulator of cell growth and differentiation.

Another study found that BICRAL was involved in the regulation of gene expression in cancer cells. The researchers found that BICRAL was able to alter the expression of genes involved in cell growth and survival, suggesting that it may be a potential drug target for cancer treatment.

BICRAL's potential as a drug target

The potential use of BICRAL as a drug target has led to a great deal of interest in the field of chromatin remodeling and gene regulation. If BICRAL is found to be a reliable drug target, it could potentially be used to treat a wide range of diseases.

One potential use for BICRAL as a drug is its ability to alter the expression of genes involved in cell growth and survival. This could make it an effective treatment for diseases such as cancer, where cells are able to grow and divide out of control.

Another potential use for BICRAL as a drug is its role in chromatin remodeling. The researchers have shown that BICRAL is involved in the regulation of gene expression, and that it plays a key role in the process of chromatin remodeling. This suggests that BICRAL may be an effective treatment for diseases where the regulation of gene expression is disrupted.

Conclusion

BICRAL is a protein that is involved in a wide range of physiological processes, including cell growth, apoptosis, and chromatin remodeling. Its role in these processes makes it an attractive target for drug development, particularly for the treatment of diseases where the regulation of gene expression is disrupted. Further research is needed to fully understand the mechanisms of BICRAL's role in chromatin remodeling and its potential as a drug target.

Protein Name: BICRA Like Chromatin Remodeling Complex Associated Protein

Functions: Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner

The "BICRAL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BICRAL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets